Aldesleukin

Generic Name: Aldesleukin

Brand Names: Proleukin

Drug Type: Biotech

CAS Number: 110942-02-4

Unique Ingredient Identifier: M89N0Q7EQR

Background: Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This recombinant form differs from native interleukin-2 in the following ways: a) Aldesleukin is not glycosylated because it is derived from E. coli; b) the molecule has no N-terminal alanine; the codon for this amino acid was deleted during the genetic engineering procedure; c) the molecule has serine substituted for cysteine at amino acid position 125.

Indication: For treatment of adults with metastatic renal cell carcinoma.

Associated Conditions: Metastatic Melanoma, Metastatic Renal Cell Carcinoma ( mRCC)

Clinical Trials

Immunotherapy With E6 T Cell Receptor (TCR) T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions

Phase 1

Terminated

Conditions: Human Papillomavirus
HPV-16
High Grade Squamous Intraepithelial Lesion

Interventions: Drug: Aldesleukin
Biological: E6 T Cell Receptor (TCR)

First Posted Date: 2017-06-23

Last Posted Date: 2021-02-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 1

Registration Number: NCT03197025

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients

Phase 1

Recruiting

Conditions: Pancreatic Cancer
Gastric Cancer
Colon Cancer
Rectal Cancer
Gastrointestinal Cancer

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Biological: Anti-KRAS G12V mTCR PBL
Drug: Aldesleukin

First Posted Date: 2017-06-19

Last Posted Date: 2025-03-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 110

Registration Number: NCT03190941

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Low Dose Interleukin-2 in Patients With Stable Ischaemic Heart Disease and Acute Coronary Syndromes

Phase 1

Completed

Conditions: Ischemic Heart Disease

Interventions: Drug: Proleukin
Drug: Placebo Injection

First Posted Date: 2017-04-14

Last Posted Date: 2021-09-14

Lead Sponsor: Cambridge University Hospitals NHS Foundation Trust

Target Recruit Count: 41

Registration Number: NCT03113773

Locations: 🇬🇧
Addenbrooke's Hospital, Cambridge, Cambridgeshire, United Kingdom

Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 1

Active, not recruiting

Conditions: Recurrent Fallopian Tube Carcinoma
Recurrent Ovarian Carcinoma
Recurrent Primary Peritoneal Carcinoma

Interventions: Biological: Aldesleukin
Drug: Cyclophosphamide
Drug: Decitabine
Biological: Genetically Engineered NY-ESO-1-specific T Lymphocytes
Other: Laboratory Biomarker Analysis

First Posted Date: 2017-01-11

Last Posted Date: 2025-03-28

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 9

Registration Number: NCT03017131

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

ILT-101 in Patients With Active Moderate to Severe Systemic Lupus Erythematosus (SLE)

Phase 2

Completed

Conditions: Systemic Lupus Erythematosus

Interventions: Drug: ILT-101
Drug: Placebo

First Posted Date: 2016-11-04

Last Posted Date: 2019-03-05

Lead Sponsor: Iltoo Pharma

Target Recruit Count: 100

Registration Number: NCT02955615

Locations: 🇪🇸
Hospital Universitario y Politécnico La Fe, Valencia, Spain
🇲🇽
Investigación y Biomedicina, Chihuahua, Mexico
🇲🇽
Clitider S.A. de C.V., Ciudad de Mexico, Mexico

and more 22 locations

ACTolog in Patients With Solid Cancers

Phase 1

Completed

Conditions: Cancer
Solid Tumor

Interventions: Drug: Fludarabine
Drug: Cyclophosphamide
Biological: IMA101 product
Biological: Recombinant human interleukin-2
Diagnostic Test: IMADetect
Drug: Atezolizumab

First Posted Date: 2016-08-23

Last Posted Date: 2025-02-04

Lead Sponsor: Immatics US, Inc.

Target Recruit Count: 38

Registration Number: NCT02876510

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

E7 TCR T Cells for Human Papillomavirus-Associated Cancers

Phase 1

Recruiting

Conditions: Cervical Intraepithelial Neoplasia
Vulvar Neoplasms
Papillomavirus Infections
Carcinoma In Situ
Vulvar Diseases

Interventions: Biological: E7 TCR cells
Drug: Aldesleukin
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2016-08-08

Last Posted Date: 2025-05-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 180

Registration Number: NCT02858310

Locations: 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States